Evaluate approved-medicine access first, then determine whether the clinic should own inventory or simply coordinate dispensing. Keep any proposed compounded preparation in a separate, product-specific clinical and legal review. FDA recommends approved medicines when they can meet the patient’s needs; compounded medicines do not undergo the same premarket review. (fda.gov)
Use this proposed route map:
| Route | What the clinic should establish | Main commercial question |
|---|---|---|
| Approved medicine purchased as clinic inventory | Purchasing eligibility, permitted handling and intended administration or dispensing | What acquisition cost and inventory exposure does the clinic actually bear? |
| Approved medicine dispensed by a pharmacy | Product acceptance, patient coverage, destination permissions and workflow | What service performance can the clinic obtain without owning medicine? |
| Manufacturer-linked patient access | Exact programme, presentation, eligibility and prescribing destination | Is the patient journey workable at ongoing—not introductory—prices? |
| Proposed compounded preparation | Applicable pathway, ingredients, prescribing rationale, facility and destination requirements | Should this arrangement proceed to commercial evaluation at all? |
LillyDirect and NovoCare describe prescription-to-patient access arrangements; those descriptions do not establish a clinic’s wholesale purchasing entitlement. (lilly.com)
First deliverable: a one-page diagram showing who prescribes, compounds if applicable, dispenses, ships, invoices, owns inventory and handles complaints. Do not accept a proposal that leaves these entities unnamed.
Explore the table row by row
A working view of the research
Approved medicine purchased as clinic inventory
- What the clinic should establish
- Purchasing eligibility, permitted handling and intended administration or dispensing
- Main commercial question
- What acquisition cost and inventory exposure does the clinic actually bear?
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers?trk=article-ssr-frontend-pulse_little-text-block&utm_source=openai
- lilly.com · Source 2 ↗https://www.lilly.com/lillydirect/faq